Recent progress in the use of periplocin, periplocymarin and periplogenin in cancer treatment

近年来,在癌症治疗中,哌利普洛辛、哌利普洛西马林和哌利普洛根宁的应用取得了进展

阅读:2

Abstract

Periplocin, periplocymarin and periplogenin are the main active components of Cortex Periplocae. The most cytotoxic constituent of Cortex Periplocae, periplocin is an alpha cardiac glycoside with a steroid core and an unsaturated five-membered lactone ring structure. Periplocymarin is a secondary alpha cardiac glycoside, which is produced by removing one molecule of glucose from periplocin, and periplogenin is the glycosidic portion and the basic unit of periplocin and periplocymarin. These three cardiac glycosides, by virtue of their unique pharmacological activities and mechanisms of action, mediate signaling pathways, mainly the retinoblastoma and p53 signaling pathways, and regulate cell cycle proteins, thereby hindering the proliferation of cancer cells and altering the cell cycle process. These glycosides also regulate caspase proteins by mediating endogenous and exogenous pathways, thereby inducing the apoptosis of cancer cells. This minireview focuses on the inhibitory effects of periplocin, periplocymarin and periplogenin on cancer, and explores their potential antitumor mechanisms.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。